1. Allavena P, Paganin C, Zhou D, Bianchi G, Sozzani S, Mantovani A (1994) Interleukin-12 is chemotactic for natural killer cells and stimulates their interaction with vascular endothelium. Blood 84:2261?2268
2. Al-Mohanna F, Saleh S, Parhar RS, Collison K (2002) IL-12-dependent nuclear factor-kappaB activation leads to de-novo synthesis and release of IL-8 and TNF-alpha in human neutrophils. J Leukoc Biol 72:995?1002
3. Ansell SM, Witzig TE, Kurtin PJ, Sloan JA, Jelinek DF, Howell KG, Markovic SN, Habermann TM, Klee GG, Atherton PJ, Erlichman C (2002) Phase I study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 99:67?74
4. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML (1997) Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3:409?417
5. Bajetta E, Del Vecchio M, Mortarini R, Nadeau R, Rakhit A, Rimassa L, Fowst C, Borri A, Anichini A, Parmiani G (1998) Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 4:75?85